Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell?

1 Nov 2018

Abstract excerpt

Immunotherapy with immune-checkpoint inhibitors (ICIs) has shifted the therapeutic landscape in lung cancer. At the same time, the clinical benefits of ICIs in unselected patients remain modest.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30631537
DOI: 10.21037/jtd.2018.09.35

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell?PMID 30631537Read ↗

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.Semantic proximity Read ↗

Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies.Semantic proximity Read ↗

Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.Semantic proximity Read ↗

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity Read ↗

The emerging development of tumor mutational burden in patients with NSCLC.Semantic proximity Read ↗

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung CancerSemantic proximity Read ↗

The landscape of tumor mutational burden and its clinical significance in patients with lung cancer: a Multi-omics study with a meta-analysisSemantic proximity Read ↗

Current status of molecular diagnostics for lung cancerSemantic proximity Read ↗

Next-Generation Sequencing of Lung Cancers: Lessons Learned and Future Directions.Semantic proximity Read ↗

Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations.Semantic proximity Read ↗

Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.Semantic proximity Read ↗

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.